Dr. Reddy’s Laboratories gets DCGI nod for phase 3 trial of Sputnik V vaccine

TAGS

Dr. Reddy’s Laboratories has secured the go-ahead from the Drugs Control General of India (DCGI) to begin phase 3 clinical trial for the Russian Covid-19 vaccine Sputnik V in India.

The Indian pharma company plans to hold the phase 3 study on 1500 volunteers as part of the randomized, double-blind, parallel-group, placebo-controlled study.

G V Prasad – Co-chairman and Managing Director of Dr. Reddy’s Laboratories said: “This is an important milestone in the progress of this pivotal clinical trial of the vaccine. We expect to commence the phase 3 study within this month and will continue to fast-track our efforts to bringing in a safe and efficacious vaccine for the Indian population.”

Dr. Reddy’s Laboratories gets approval from the DCGI for conducting phase 3 clinical trial of Sputnik V Covid-19 vaccine

Dr. Reddy’s Laboratories gets approval from the DCGI for conducting phase 3 clinical trial of Sputnik V Covid-19 vaccine. Photo courtesy of The Russian Direct Investment Fund.

Earlier this month, Dr. Reddy’s Laboratories said that the Sputnik V Covid-19 vaccine met the primary endpoint of safety in a phase 2 trial in India. Subsequently, an independent data and safety monitoring board (DSMB) examined the safety data from the phase 2 clinical trial of the Sputnik V Covid-19 vaccine and recommended the phase 3 enrollment.

See also  Delhivery to strengthen D2C offering with investment in Vinculum

In its report, the DSMB reported that no safety concerns were noted and the phase 2 clinical trial met the primary endpoints of safety.

Dr. Reddy’s Laboratories has a partnership with the Russian Direct Investment Fund (RDIF) for bringing the Russian Covid-19 vaccine Sputnik V to India.


Discover more from Business-News-Today.com

Subscribe to get the latest posts sent to your email.

See also  GE Aerospace deepens ties with India to fuel aviation growth amid global supply chain challenges

CATEGORIES
TAGS
Share This